Biocon and Genentech have reached a global patent settlement and licence agreement establishing planned launch windows for Pebrilzo, Biocon's pertuzumab biosimilar to Perjeta.

The FDA has expanded approval of two Roche HER2 companion diagnostics to identify patients with metastatic gastroesophageal adenocarcinoma who may be eligible for ZIIHERA treatment.

Biocon has secured a 10-year pertuzumab supply partnership in Brazil under the country's Productive Development Partnership programme.

The FDA has granted accelerated approval to Hyrnuo for first-line treatment of adults with locally advanced or metastatic non-squamous non-small cell lung cancer carrying activating HER2/ERBB2 tyrosine kinase domain mutations.

The agreement gives Cipla exclusive rights to develop and commercialise the investigational HER2-targeted bispecific antibody-drug conjugate TQB2102 across India, South Africa and five additional emerging markets.